To the full analysis
Buyback calculator for Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting stock: key metrics
300347.SZHangzhou Tigermed Consulting had an operating margin of 14.8% and a return on invested capital (ROIC) of 3.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2009 | 37.6% | 11.4% | 12.4% |
| 2010 | 48.1% | 28.1% | 25.8% |
| 2011 | 47.7% | 28.5% | 24.7% |
| 2012 | 48.8% | 26.2% | 26.6% |
| 2013 | 45.1% | 30.3% | 27.9% |
| 2014 | 47.3% | 27.1% | 20.1% |
| 2015 | 44.1% | 22.3% | 16.3% |
| 2016 | 38.0% | 16.9% | 12.0% |
| 2017 | 42.9% | 24.7% | 17.8% |
| 2018 | 43.1% | 25.9% | 20.5% |
| 2019 | 46.5% | 38.7% | 30.0% |
| 2020 | 47.4% | 69.6% | 54.8% |
| 2021 | 43.6% | 70.9% | 55.1% |
| 2022 | 39.6% | 36.4% | 28.3% |
| 2023 | 38.5% | 33.7% | 27.4% |
| 2024 | 34.0% | 10.1% | 6.1% |
| 2025 | 27.4% | 14.8% | 13.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2009 | 18.4% | 24.7% | 11.6% |
| 2010 | 34.0% | 76.5% | 26.4% |
| 2011 | 33.9% | 81.8% | 25.6% |
| 2012 | 9.8% | 59.3% | 9.2% |
| 2013 | 12.6% | 49.1% | 11.6% |
| 2014 | 14.5% | 27.8% | 9.2% |
| 2015 | 15.6% | 18.4% | 9.7% |
| 2016 | 8.6% | 11.4% | 5.9% |
| 2017 | 12.1% | 16.3% | 8.4% |
| 2018 | 16.6% | 17.4% | 10.1% |
| 2019 | 19.9% | 25.1% | 11.1% |
| 2020 | 10.9% | 32.7% | 9.0% |
| 2021 | 15.9% | 32.5% | 12.1% |
| 2022 | 10.2% | 15.0% | 7.3% |
| 2023 | 9.6% | 11.6% | 6.8% |
| 2024 | 2.0% | 2.0% | 1.4% |
| 2025 | 4.2% | 3.3% | 3.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 16 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.